Human immunodeficiency virus vaccine is under clinical development by Aelix Therapeutics and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Human immunodeficiency virus vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human immunodeficiency virus vaccine overview
The vaccine candidate is under development for the treatment of HIV-1 infections. It comprises of HIVACAT T-cell immunogen (HTI) which is a chemically synthesized chimeric protein-encoding viral proteins gag, pol, vif and nef. The HTI immunogen is administered through an heterologous prime-boost vaccination that includes two components, a DNA vaccine prime (DNA.HTI) and a viral vaccine boost (MVA.HTI). It is administered through intramuscular route.
Aelix Therapeutics overview
Aelix Therapeutics, a spinoff of HIVACAT, is a biotechnology company that discovers and develops vaccines for the treatment of HIV infection. The company’s lead vaccine program includes HTI immunogen (HIVACAT T-cell immunogen) which is based on an innovative T cell vaccine immunogen design that directs the body’s immune defense to the most vulnerable parts of HIV. It develops and commercializes HTI immunogen. Aelix Therapeutics is headquartered in Barcelona, Spain.
For a complete picture of Human immunodeficiency virus vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
